NCT05106309View on ClinicalTrials.gov

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

February 24, 2022

Study Completion Date

February 24, 2022

Conditions
Schizophrenia
Interventions
DRUG

10 mg CVL-231 as IR formulation

Tablets

DRUG

30 mg CVL-231 as slow-release MR formulation

Capsules

DRUG

30 mg CVL-231 as medium release MR formulation

Capsules

DRUG

30 mg CVL-231 as fast release MR formulation

Capsules

DRUG

30 mg CVL-231 Target Release, Fasted

Capsules

DRUG

30 mg CVL-231 Target Release, Fed

Capsules

Trial Locations (1)

85283

Celerion Inc., Tempe

Sponsors
All Listed Sponsors
lead

Cerevel Therapeutics, LLC

INDUSTRY

NCT05106309 - Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants | Biotech Hunter | Biotech Hunter